# | Title | Journal | Year | Citations |
---|
1 | Hyperleukocytic Leukemias and Leukostasis: A Review of Pathophysiology, Clinical Presentation and Management | Leukemia and Lymphoma | 2000 | 311 |
2 | CD19 Antigen in Leukemia and Lymphoma Diagnosis and Immunotherapy | Leukemia and Lymphoma | 1995 | 275 |
3 | Triptolide, A Novel Immunosuppressive and Anti-Inflammatory Agent Purified from a Chinese Herb Tripterygium Wilfordii Hook F | Leukemia and Lymphoma | 2001 | 269 |
4 | Management of adverse events associated with idelalisib treatment: expert panel opinion | Leukemia and Lymphoma | 2015 | 268 |
5 | Indirubin and Meisoindigo in the Treatment of Chronic Myelogenous Leukemia in China | Leukemia and Lymphoma | 2002 | 255 |
6 | Granulocytic sarcoma: 32 cases and review of the literature | Leukemia and Lymphoma | 2006 | 247 |
7 | 18-FDG-PET as a Prognostic Indicator in the Treatment of Aggressive Non-Hodgkin's Lymphoma-Comparison with CT | Leukemia and Lymphoma | 2000 | 244 |
8 | Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma | Leukemia and Lymphoma | 2013 | 236 |
9 | Rituximab-related viral infections in lymphoma patients | Leukemia and Lymphoma | 2007 | 235 |
10 | Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib | Leukemia and Lymphoma | 2008 | 233 |
11 | Preclinicalversusclinical drug combination studies | Leukemia and Lymphoma | 2008 | 233 |
12 | Pathways and mechanisms of venetoclax resistance | Leukemia and Lymphoma | 2017 | 203 |
13 | Improved Outcome of Zygomycosis in Patients with Hematological Diseases? | Leukemia and Lymphoma | 2004 | 202 |
14 | Risk of Febrile Neutropenia among Patients with Intermediate-grade non-Hodgkin's Lymphoma Receiving CHOP Chemotherapy | Leukemia and Lymphoma | 2003 | 199 |
15 | Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases | Leukemia and Lymphoma | 2011 | 199 |
16 | Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel | Leukemia and Lymphoma | 2011 | 198 |
17 | Epidemiology of myeloproliferative neoplasms in the United States | Leukemia and Lymphoma | 2014 | 195 |
18 | Multicenter Phase 2 Trial of Rituximab for Waldenström Macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98) | Leukemia and Lymphoma | 2004 | 193 |
19 | Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma | Leukemia and Lymphoma | 2010 | 187 |
20 | Renal failure in multiple myeloma: Incidence, correlations, and prognostic significance | Leukemia and Lymphoma | 2007 | 186 |
21 | Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma | Leukemia and Lymphoma | 2008 | 185 |
22 | Hematopoeitic stem cell transplantation for adult T cell leukemia-lymphoma: Who is the best candidate? | Leukemia and Lymphoma | 2017 | 181 |
23 | Results of First Salvage Therapy for Patients Refractory to a Fludarabine Regimen in Chronic Lymphocytic Leukemia | Leukemia and Lymphoma | 2002 | 180 |
24 | Mastocytosis: Pathology, genetics, and current options for therapy | Leukemia and Lymphoma | 2005 | 180 |
25 | Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia | Leukemia and Lymphoma | 2008 | 176 |
26 | Primary Non-Hodgkin's Lymphoma of the Liver | Leukemia and Lymphoma | 1998 | 175 |
27 | Asparaginase-associated toxicity in children with acute lymphoblastic leukemia | Leukemia and Lymphoma | 2016 | 175 |
28 | L-Asparaginase and PEG Asparaginase— Past, Present, and Future | Leukemia and Lymphoma | 1993 | 174 |
29 | The Cytogenetic Scenario of Chronic Myeloid Leukemia | Leukemia and Lymphoma | 1993 | 171 |
30 | Clinical Features, Treatment and Outcome in a Series of 93 Patients with Low-Grade Gastric MALT Lymphoma | Leukemia and Lymphoma | 1997 | 171 |
31 | Targeting the apoptosis pathway in hematologic malignancies | Leukemia and Lymphoma | 2014 | 169 |
32 | Autoimmune Phenomena in Patients with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia | Leukemia and Lymphoma | 2002 | 163 |
33 | Type I Interferon as a Link Between Innate and Adaptive Immunity through Dendritic Cell Stimulation | Leukemia and Lymphoma | 2004 | 162 |
34 | Apoptosis Overview Emphasizing the Role of Oxidative Stress, DNA Damage and Signal- Transduction Pathways | Leukemia and Lymphoma | 1995 | 161 |
35 | Serum β2-Microglobulin and Serum Thymidine Kinase are Independent Predictors of Progression-Free Survival in Chronic Lymphocytic Leukemia and Immunocytoma | Leukemia and Lymphoma | 1996 | 161 |
36 | Recent Results on the Biology of Hodgkin and Reed-Sternberg cells: II. Continuous Cell Lines | Leukemia and Lymphoma | 1993 | 157 |
37 | Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients | Leukemia and Lymphoma | 2006 | 157 |
38 | A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia | Leukemia and Lymphoma | 2015 | 155 |
39 | Ovarian Injury and Modern Options to Preserve Fertility in Female Cancer Patients Treated with High Dose Radio-Chemotherapy for Hemato-Oncological Neoplasias and other Cancers | Leukemia and Lymphoma | 1999 | 153 |
40 | Skin lesions in chronic lymphocytic leukemia | Leukemia and Lymphoma | 2007 | 152 |
41 | Bone marrow-derived mesenchymal stem cells | Leukemia and Lymphoma | 2005 | 151 |
42 | Integrin-Mediated Drug Resistance in Multiple Myeloma | Leukemia and Lymphoma | 2000 | 149 |
43 | Delayed intensive care unit admission is associated with increased mortality in patients with cancer with acute respiratory failure | Leukemia and Lymphoma | 2013 | 149 |
44 | Fludarabine and Arabinosylcytosine Therapy of Refractory and Relapsed Acute Myelogenous Leukemia | Leukemia and Lymphoma | 1993 | 147 |
45 | Abnormal T-cell Function in B-cell Chronic Lymphocytic Leukaemia | Leukemia and Lymphoma | 2003 | 145 |
46 | Regulation of Hematopoiesis by Microvascular Endothelium | Leukemia and Lymphoma | 1997 | 144 |
47 | Cardiac morbidity following modern treatment for Hodgkin lymphoma: Supra-additive cardiotoxicity of doxorubicin and radiation therapy | Leukemia and Lymphoma | 2008 | 144 |
48 | Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates | Leukemia and Lymphoma | 2008 | 143 |
49 | Enhancer of zeste homolog 2 (EZH2) inhibitors | Leukemia and Lymphoma | 2018 | 143 |
50 | Detection of molecular targets on the surface of CD34+/CD38− stem cells in various myeloid malignancies | Leukemia and Lymphoma | 2006 | 140 |